The US District Court today lifted a temporary restraining order on Eli Lilly stemming from the lawsuit against it being pursued by Amylin. Amylin filed suit against Lilly when the latter announced its intention to sell Boehringer Ingelheim's type 2 diabetes treatment, linagliptin, with the same sales force it would use to sell Amylin's competitive products Byetta and Bydureon (when licensed). Amylin saw this as a major conflict of interest.
The Court decided not to offer Amylin injunctive relief, but Amylin is still free to pursue its suit and monetary damages. Lilly is happy to be freed and says it looks forward to further litigation where it will be absolved.
Posted by Bruce Lehr June 9th 2011.